422 related articles for article (PubMed ID: 33013832)
21. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
Man YG; Gardner WA
Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
[TBL] [Abstract][Full Text] [Related]
22. Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis.
Lee SH; Luong R; Johnson DT; Cunha GR; Rivina L; Gonzalgo ML; Sun Z
Oncogene; 2016 Feb; 35(6):702-14. PubMed ID: 25893287
[TBL] [Abstract][Full Text] [Related]
23. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
24. N-glycans and metastasis in galectin-3 transgenic mice.
More SK; Srinivasan N; Budnar S; Bane SM; Upadhya A; Thorat RA; Ingle AD; Chiplunkar SV; Kalraiya RD
Biochem Biophys Res Commun; 2015 May; 460(2):302-7. PubMed ID: 25791476
[TBL] [Abstract][Full Text] [Related]
25. Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer.
Gentilini LD; Jaworski FM; Tiraboschi C; Pérez IG; Kotler ML; Chauchereau A; Laderach DJ; Compagno D
Oncotarget; 2017 Jul; 8(27):44654-44668. PubMed ID: 28591719
[TBL] [Abstract][Full Text] [Related]
26. miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells.
Liu R; Liu C; Zhang D; Liu B; Chen X; Rycaj K; Jeter C; Calhoun-Davis T; Li Y; Yang T; Wang J; Tang DG
Oncotarget; 2016 Aug; 7(35):56628-56642. PubMed ID: 27447749
[TBL] [Abstract][Full Text] [Related]
27. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.
Kang BH; Tavecchio M; Goel HL; Hsieh CC; Garlick DS; Raskett CM; Lian JB; Stein GS; Languino LR; Altieri DC
Br J Cancer; 2011 Feb; 104(4):629-34. PubMed ID: 21285984
[TBL] [Abstract][Full Text] [Related]
28. Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets.
Grosset AA; Labrie M; Vladoiu MC; Yousef EM; Gaboury L; St-Pierre Y
Oncotarget; 2016 Apr; 7(14):18183-203. PubMed ID: 26933916
[TBL] [Abstract][Full Text] [Related]
29. Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy.
Ciavarra RP; Holterman DA; Brown RR; Mangiotti P; Yousefieh N; Wright GL; Schellhammer PF; Glass WF; Somers KD
J Immunother; 2004; 27(1):13-26. PubMed ID: 14676630
[TBL] [Abstract][Full Text] [Related]
30. Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness.
Zhou X; Li D; Wang X; Zhang B; Zhu H; Zhao J
Oncotarget; 2015 Feb; 6(5):3111-22. PubMed ID: 25605013
[TBL] [Abstract][Full Text] [Related]
31. β4 Integrin signaling induces expansion of prostate tumor progenitors.
Yoshioka T; Otero J; Chen Y; Kim YM; Koutcher JA; Satagopan J; Reuter V; Carver B; de Stanchina E; Enomoto K; Greenberg NM; Scardino PT; Scher HI; Sawyers CL; Giancotti FG
J Clin Invest; 2013 Feb; 123(2):682-99. PubMed ID: 23348745
[TBL] [Abstract][Full Text] [Related]
32. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
33. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis.
Fukumori T; Takenaka Y; Yoshii T; Kim HR; Hogan V; Inohara H; Kagawa S; Raz A
Cancer Res; 2003 Dec; 63(23):8302-11. PubMed ID: 14678989
[TBL] [Abstract][Full Text] [Related]
34. Endogenous galectin-3 expression levels modulate immune responses in galectin-3 transgenic mice.
Chaudhari AD; Gude RP; Kalraiya RD; Chiplunkar SV
Mol Immunol; 2015 Dec; 68(2 Pt A):300-11. PubMed ID: 26442663
[TBL] [Abstract][Full Text] [Related]
35. Expression analysis of putative stem cell markers in human benign and malignant prostate.
Ugolkov AV; Eisengart LJ; Luan C; Yang XJ
Prostate; 2011 Jan; 71(1):18-25. PubMed ID: 20583131
[TBL] [Abstract][Full Text] [Related]
36. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.
Zhong C; Saribekyan G; Liao CP; Cohen MB; Roy-Burman P
Cancer Res; 2006 Feb; 66(4):2188-94. PubMed ID: 16489020
[TBL] [Abstract][Full Text] [Related]
37. beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.
Goel HL; Breen M; Zhang J; Das I; Aznavoorian-Cheshire S; Greenberg NM; Elgavish A; Languino LR
Cancer Res; 2005 Aug; 65(15):6692-700. PubMed ID: 16061650
[TBL] [Abstract][Full Text] [Related]
38. p63 cytoplasmic aberrance is associated with high prostate cancer stem cell expression.
Ferronika P; Triningsih FX; Ghozali A; Moeljono A; Rahmayanti S; Shadrina AN; Naim AE; Wudexi I; Arnurisa AM; Nanwani ST; Harijadi A
Asian Pac J Cancer Prev; 2012; 13(5):1943-8. PubMed ID: 22901151
[TBL] [Abstract][Full Text] [Related]
39. Hedgehog overexpression leads to the formation of prostate cancer stem cells with metastatic property irrespective of androgen receptor expression in the mouse model.
Chang HH; Chen BY; Wu CY; Tsao ZJ; Chen YY; Chang CP; Yang CR; Lin DP
J Biomed Sci; 2011 Jan; 18(1):6. PubMed ID: 21241512
[TBL] [Abstract][Full Text] [Related]
40. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Narayanan BA; Narayanan NK; Pttman B; Reddy BS
Prostate; 2006 Feb; 66(3):257-65. PubMed ID: 16175586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
